Pacira BioSciences (FRA:82P) NonCurrent Deferred Liabilities: €3.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:82P Pacira BioSciences Inc FRA:82P
81 GF Score
Price €21.60
GF Value €25.68
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences NonCurrent Deferred Liabilities?

Pacira BioSciences FRA:82P -1.82% 81 NonCurrent Deferred Liabilities is €3.5 Mil as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 81/100 and a GF Value™ of €25.68. The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Pacira BioSciences's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €3.5 Mil.

Pacira BioSciences NonCurrent Deferred Liabilities Related Terms

Pacira BioSciences NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences NonCurrent Deferred Liabilities Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.60

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.47 3.97 3.91 3.60 3.54
FRA:82P
81GF Score
Pacira BioSciences Inc FRA:82P
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €3.5 Mil mean?
Pacira BioSciences (FRA:82P) has a NonCurrent Deferred Liabilities of €3.5 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' NonCurrent Deferred Liabilities too high?
Pacira BioSciences' current NonCurrent Deferred Liabilities is €3.5 Mil. Overall, Pacira BioSciences has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' NonCurrent Deferred Liabilities compare to ETON and AMPH?
Pacira BioSciences' NonCurrent Deferred Liabilities of €3.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current NonCurrent Deferred Liabilities is €3.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current NonCurrent Deferred Liabilities of €3.5 Mil. The stock's GF Value™ is €25.68, compared to a current price of €21.60 — trading 15.9% below its estimated fair value. The current NonCurrent Deferred Liabilities is €3.5 Mil. Pacira BioSciences' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current NonCurrent Deferred Liabilities is €3.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €21.60 is trading 15.9% below its estimated GF Value™ of €25.68.

Key valuation signals for FRA:82P:

  • NonCurrent Deferred Liabilities: €3.5 Mil
  • GF Value™: €25.68 vs. price of €21.60 (15.9% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
81GF Score

Get the complete analysis for FRA:82P

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.60
Price
€25.68
GF Value